CLOVIS ONCOLOGY INC (CLVS)
US1894641000 - Common Stock
| MRQ (2022-9-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 58.32M | 143.43M | 240.20M | 161.80M | 221.90M | |||
| Marketable Securities | N/A | N/A | 0.00 | 134.80M | 298.30M | |||
| Receivables | 22.62M | 33.67M | 30.60M | 34.70M | 15.20M | |||
| Inventories | 11.42M | 13.69M | 30.70M | 26.50M | 27.10M | |||
| Other Current Assets | 9.85M | 7.30M | 9.30M | 8.70M | 9.90M | |||
| Total Current Assets | 102.21M | 198.09M | 310.80M | 366.50M | 572.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 21.52M | 25.66M | 42.50M | 43.40M | 26.50M | |||
| Goodwill | 63.07M | 63.07M | 63.10M | 63.10M | 63.10M | |||
| Intangibles | 56.34M | 60.37M | 65.70M | 62.90M | 51.90M | |||
| Other Non-Current Assets | 103.63M | 125.64M | 123.40M | 133.70M | 149.70M | |||
| Total Non-Current Assets | 244.57M | 274.75M | 294.80M | 303.10M | 291.30M | |||
| TOTAL ASSETS | 346.77M | 472.83M | 605.60M | 669.60M | 863.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 660.38M | 8.50M | 64.20M | 0.00 | 1.00M | |||
| Accrued Expenses | 68.79M | 87.83M | 93.10M | 97.30M | 95.40M | |||
| Accounts Payable | 18.12M | 27.31M | 26.70M | 32.20M | 28.50M | |||
| Other Current Liabilities | 581.00K | 1.58M | 900.00K | 3.50M | 800.00K | |||
| Total Current Liabilities | 747.87M | 125.21M | 184.90M | 133.10M | 125.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 606.73M | 545.80M | 679.70M | 575.50M | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 16.79M | 19.73M | 33.60M | 31.00M | 15.90M | |||
| Total Non-Current Liabilities | 16.79M | 626.46M | 579.40M | 710.80M | 591.40M | |||
| TOTAL LIABILITIES | 764.66M | 751.67M | 764.30M | 843.90M | 717.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -3.06B | -2.88B | -2.61B | -2.24B | -1.84B | |||
| Additional Paid In Capital | 2.69B | 2.64B | 2.50B | 2.11B | 2.03B | |||
| Common Shares | 145.00K | 129.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -40.77M | -43.29M | -44.20M | -44.70M | -44.50M | |||
| Shares Outstanding | 144.80M | 129.11M | 103.70M | 55.00M | 52.80M | |||
| Tangible Book Value per Share | -3.71 | -3.12 | -2.77 | -5.46 | 0.60 | |||
| Total Shareholders' Equity | -417.89M | -278.84M | -158.70M | -174.30M | 146.50M | |||
| TOTAL LIABILITIES AND EQUITY | 346.77M | 472.83M | 605.60M | 669.60M | 863.60M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | -2.18 | -3.44 | -3.90 | 3.93 | |||
| Current Ratio | 0.14 | 1.58 | 1.68 | 2.75 | 4.55 | |||
| Return On Assets (ROA) | -72.64% | -55.94% | -60.96% | -59.80% | -42.61% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | N/A | -251.19% | |||
All data in USD